Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to $17.6 million.

  • RxSight's Accumulated Expenses rose 172.03% to $17.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.6 million, marking a year-over-year increase of 172.03%. This contributed to the annual value of $20.4 million for FY2024, which is 3359.14% up from last year.
  • Latest data reveals that RxSight reported Accumulated Expenses of $17.6 million as of Q3 2025, which was up 172.03% from $15.9 million recorded in Q2 2025.
  • In the past 5 years, RxSight's Accumulated Expenses registered a high of $20.4 million during Q4 2024, and its lowest value of $4.8 million during Q2 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $12.2 million (2022), whereas its average is $11.9 million.
  • As far as peak fluctuations go, RxSight's Accumulated Expenses skyrocketed by 8828.46% in 2021, and later surged by 172.03% in 2025.
  • RxSight's Accumulated Expenses (Quarter) stood at $7.9 million in 2021, then soared by 61.24% to $12.7 million in 2022, then rose by 20.26% to $15.2 million in 2023, then skyrocketed by 33.59% to $20.4 million in 2024, then dropped by 13.44% to $17.6 million in 2025.
  • Its Accumulated Expenses was $17.6 million in Q3 2025, compared to $15.9 million in Q2 2025 and $14.6 million in Q1 2025.